Market niche Target translational proteomics buyers in biotech and pharma seeking high-sensitivity multiplex protein analysis with small sample requirements. Highlight LUNARIS platform as scalable, image-based QC, and integrated data management to appeal to R&D and clinical study teams.

Capital efficiency Position the company as a cost-conscious partner for early-stage biotech startups and CROs with a <$1M revenue profile and $15M funding, offering modular kits and reader systems to accelerate assay development without heavy upfront CAPEX.

Therapeutic focus Emphasize opportunities in immuno-oncology, ophthalmology, and model-to-man research where multiplex panels (chemokines, T cell markers, Th17) align with translational proteomics needs, presenting LUNARIS kits as enabling deeper biomarker insights for drug development.

Global collaboration Leverage past partnerships (SERI) and international reach from Cologne to pursue collaborations with eye research centers, academic institutions, and multinational pharma, offering co-development and kit customization to expand adoption.

Technology leadership Differentiate with beads-on-a-chip technology, fully integrated QC and data processing, and a track record of platform and kit launches since 2015 to attract early adopters seeking cutting-edge multiplex assays and robust data workflows.